Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
January 19, 2021 08:00 ET
|
Advaxis, Inc.
PRINCETON, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
December 22, 2020 13:42 ET
|
Advaxis, Inc.
PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
November 27, 2020 12:07 ET
|
Advaxis, Inc.
PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
November 24, 2020 08:30 ET
|
Advaxis, Inc.
PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
November 23, 2020 16:05 ET
|
Advaxis, Inc.
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 09, 2020 08:01 ET
|
Advaxis, Inc.
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA® Biomarker data confirms on-mechanism activation of innate...
Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
October 26, 2020 08:00 ET
|
Advaxis, Inc.
Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA Approximate 50% improvement in disease control rate versus the rates reported in other checkpoint...
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
October 15, 2020 08:00 ET
|
Advaxis, Inc.
PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
September 29, 2020 08:30 ET
|
Advaxis, Inc.
PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
September 24, 2020 08:00 ET
|
Advaxis, Inc.
Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4...